Jie Wu

Also affiliated with Changzhi Medical College, Ministry of Agriculture, University of Oklahoma Health Sciences Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations”.

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Annals of Oncology(2020)10.1016/j.annonc.2020.10.599

N/A

0DataRank · unranked

249 citations

Tao Shen, S. Terzyan, X. Liu, Xueqing Hu, Khadijah Patel +8 more

Precision therapy for RET-altered cancers with RET inhibitors

Trends in cancer(2021)10.1016/j.trecan.2021.07.003

N/A

0DataRank · unranked

174 citations

Vamsidhar Velcheti, Blaine H. M. Mooers, Jie Wu, Vivek Subbiah, Kyaw Zin Thein

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

npj Precision Oncology(2021)10.1038/s41698-021-00188-x

N/A

0DataRank · unranked

49 citations

Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu +1 more

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Pharmacology & Therapeutics(2023)10.1016/j.pharmthera.2023.108344

N/A

0DataRank · unranked

48 citations

Ernesto G. Miranda-Morales, Petra den Hollander, Alex Friedlaender, Herman O. Sintim, Jie Wu +3 more

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0629

N/A

0DataRank · unranked

14 citations

Neetu Dayal, Xueqing Hu, Elizabeth Larocque, Nimishetti Naganna, Tao Shen +6 more

The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases

Drug Resistance Updates(2023)10.1016/j.drup.2023.100958

N/A

0DataRank · unranked

12 citations

Xuan Liu, Ujjwol Khatri, Jie Wu, Xueqing Hu

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

Annals of Oncology(2023)10.1016/j.annonc.2023.07.002

N/A

0DataRank · unranked

7 citations

Mimi I. Hu, Maria E. Cabanillas, Jie Wu, Funda Meric‐Bernstam, Vivek Subbiah +1 more

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion–Positive Breast Cancer and Beyond

Cancer Research(2023)10.1158/0008-5472.can-23-1021

N/A

0DataRank · unranked

3 citations

Vivek Subbiah, Jie Wu

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology(2024)10.1038/s41698-024-00563-4

N/A

0DataRank · unranked

25 citations

Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven I. Sherman +8 more

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model

Cancer Letters(2025)10.1016/j.canlet.2025.217444

N/A

0DataRank · unranked

3 citations

Mohamed A. Gouda, Shriya Pandey, Neeraj Chauhan, Tao Shen, Xueqing Hu +5 more

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy

RSC Medicinal Chemistry(2025)10.1039/d5md00245a

N/A

0DataRank · unranked

1 citations

Neetu Dayal, Kofi Baffour-Awuah Owusu, Mandeep Kaur Hunjan, Shriya Pandey, H. Harper +14 more